$ACON
Aclarion, Inc. Stock $acon

$acon Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000168316824001821 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$10.11K	$13.80K	$75.40K
YoY Change	-60.29%	-38.72%	24.74%
Cost Of Revenue	$19.48K	$19.42K	$75.73K
YoY Change	11.61%	12.32%	15.98%
Gross Profit	-$9.362K	-$5.620K	-$330.00
YoY Change	-216.73%	-207.46%	-93.2%
Gross Profit Margin	-92.56%	-40.72%	-0.44%
Selling, General & Admin	$1.027M	$900.0K	$4.002M
YoY Change	4.27%	-17.59%	-20.03%
% of Gross Profit
Research & Development	$239.0K	$220.7K	$873.3K
YoY Change	16.95%	-7.97%	-19.79%
% of Gross Profit
Depreciation & Amortization	$45.11K	$42.67K	$162.7K
YoY Change	14.58%	-17.58%	3514.89%
% of Gross Profit
Operating Expenses	$1.266M	$1.121M	$4.876M
YoY Change	6.45%	-15.86%	-19.99%
Operating Profit	-$1.275M	-$1.126M	-$4.876M
YoY Change	7.96%	-15.11%	-20.05%
Interest Expense	$335.8K	-$65.57K	$38.35K
YoY Change	-24435.07%	3067.63%	-97.46%
% of Operating Profit
Other Income/Expense, Net	-$1.124M	-$73.44K	-$73.74K
YoY Change	136948.17%	91700.0%	-95.11%
Pretax Income	-$2.399M	-$1.265M	-$4.911M
YoY Change	102.72%	-4.78%	-35.42%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.399M	-$1.265M	-$4.911M
YoY Change	102.72%	-4.78%	-35.42%
Net Earnings / Revenue	-23720.61%	-9169.2%	-6513.75%
Basic Earnings Per Share	-$0.44		-$8.82
Diluted Earnings Per Share	-$0.44	-$2.27	-$8.82
COMMON SHARES
Basic Shares Outstanding	7.154M shares	8.793M shares	556.8K shares
Diluted Shares Outstanding	5.443M shares		556.8K shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$2.183M	$1.021M	$1.071M
YoY Change	385.03%	-30.67%	-27.28%
Cash & Equivalents	$2.133M	$1.021M	$1.021M
Short-Term Investments	$50.00K		$50.00K
Other Short-Term Assets	$338.3K	$255.0K	$204.9K
YoY Change	61.1%	-48.67%	-58.77%
Inventory
Prepaid Expenses
Receivables	$17.21K	$13.27K	$13.27K
Other Receivables	$160.00	$0.00	$150.00
Total Short-Term Assets	$2.538M	$1.289M	$1.289M
YoY Change	275.75%	-35.15%	-35.15%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.486K	$1.780K	$1.780K
YoY Change	-47.73%	-46.8%	-46.87%
Goodwill
YoY Change
Intangibles	$1.187M	$1.169M
YoY Change	0.37%	-3.77%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.189M	$1.170M	$1.170M
YoY Change	0.26%	-3.89%	-3.89%
TOTAL ASSETS
Total Short-Term Assets	$2.538M	$1.289M	$1.289M
Total Long-Term Assets	$1.189M	$1.170M	$1.170M
Total Assets	$3.727M	$2.460M	$2.460M
YoY Change	100.24%	-23.28%	-23.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$195.7K	$760.5K	$758.8K
YoY Change	-64.07%	64.55%	65.84%
Accrued Expenses	$288.1K	$857.7K	$857.7K
YoY Change	51.65%	40.43%	40.43%
Deferred Revenue
YoY Change
Short-Term Debt	$670.2K	$1.126M	$1.126M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.222M	$3.188M	$3.188M
YoY Change	65.92%	124.77%	124.77%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.222M	$3.188M	$3.188M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$1.222M	$3.188M	$3.188M
YoY Change	65.11%	124.77%	124.77%
SHAREHOLDERS EQUITY
Retained Earnings	-$46.68M	-$44.28M
YoY Change	15.11%	10.96%
Common Stock	$72.00	$8.00
YoY Change	-8.86%	-89.87%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.505M	-$728.0K	-$728.0K
YoY Change
Total Liabilities & Shareholders Equity	$3.727M	$2.460M	$2.460M
YoY Change	100.24%	-23.28%	-23.28%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$2.399M	-$1.265M	-$4.911M
YoY Change	102.72%	-4.78%	-35.42%
Depreciation, Depletion And Amortization	$45.11K	$42.67K	$162.7K
YoY Change	14.58%	-17.58%	3514.89%
Cash From Operating Activities	-$2.239M	-$736.9K	-$3.647M
YoY Change	120.96%	-35.07%	-31.37%
INVESTING ACTIVITIES
Capital Expenditures	$63.66K	$29.52K	$119.5K
YoY Change	443.17%	-38.82%	-42.78%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$63.66K	-$29.52K	-$119.5K
YoY Change	443.15%	-38.82%	-42.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$1.464M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.414M	1.625M	3.315M
YoY Change			-49.41%
NET CHANGE
Cash From Operating Activities	-$2.239M	-736.9K	-3.647M
Cash From Investing Activities	-$63.66K	-29.52K	-119.5K
Cash From Financing Activities	$3.414M	1.625M	3.315M
Net Change In Cash	$1.112M	858.3K	-451.7K
YoY Change	-208.46%	-172.53%	-143.85%
FREE CASH FLOW
Cash From Operating Activities	-$2.239M	-$736.9K	-$3.647M
Capital Expenditures	$63.66K	$29.52K	$119.5K
Free Cash Flow	-$2.302M	-$766.5K	-$3.766M
YoY Change	124.64%	-35.23%	-31.8%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001635077
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	ACON	Exercise Of Convertible Note Warrants Value ExerciseOfConvertibleNoteWarrantsValue		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	true
CY2023	dei	Document Fin Stmt Restatement Recovery Analysis Flag DocumentFinStmtRestatementRecoveryAnalysisFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	4672826	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	7153500	shares
CY2022	dei	Auditor Firm AuditorFirmId	596
CY2023	dei	Auditor Name AuditorName	Haynie & Company
CY2023	dei	Auditor Location AuditorLocation	Salt Lake City, Utah
CY2023	dei	Auditor Firm AuditorFirmId	457
CY2022	dei	Auditor Name AuditorName	CohnReznick LLP
CY2022	dei	Auditor Location AuditorLocation	Sunrise, Florida
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1021069	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1472806	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	10000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	10000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13270	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18569	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	245030	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	199701	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1289369	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	1701076	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1782	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3346	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1168623	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	1210207	usd
CY2023Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1170405	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1213553	usd
CY2023Q4	us-gaap	Assets Assets	2459774	usd
CY2022Q4	us-gaap	Assets Assets	2914629	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	760535	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	462202	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	857722	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	226469	usd
CY2023Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	1125724	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	0	usd
CY2023Q4	ACON	Warrant Liability Current WarrantLiabilityCurrent	289165	usd
CY2022Q4	ACON	Warrant Liability Current WarrantLiabilityCurrent	0	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	121326	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2023Q4	ACON	Liability To Issue Equity LiabilityToIssueEquity	33297	usd
CY2022Q4	ACON	Liability To Issue Equity LiabilityToIssueEquity	0	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3187769	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	688671	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	825459	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	825459	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	491345	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	491345	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	8	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	5	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	43553523	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	41596106	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-44281526	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-39370153	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-727995	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2225958	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2459774	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2914629	usd
CY2023	us-gaap	Revenues Revenues	75404	usd
CY2022	us-gaap	Revenues Revenues	60444	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	75728	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	65298	usd
CY2023	us-gaap	Gross Profit GrossProfit	-324	usd
CY2022	us-gaap	Gross Profit GrossProfit	-4854	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	873336	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3245317	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3990719	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	4875657	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	5556714	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-4875981	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-5561568	usd
CY2023	us-gaap	Interest Expense InterestExpense	608288	usd
CY2022	us-gaap	Interest Expense InterestExpense	1507546	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	646319	usd
CY2022	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
CY2023	ACON	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	-72862	usd
CY2022	ACON	Loss On Issuance Of Warrants LossOnIssuanceOfWarrants	0	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-562	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	521	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-35393	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1507025	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4911374	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7068593	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4911374	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-7068593	usd
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	-0	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	415523	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4911374	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-7484116	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.82
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.82
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-19.61
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-19.61
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	556808	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	556808	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	381598	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	381598	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-12831606	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1186658	usd
CY2022	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	415523	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	7102287	usd
CY2022	ACON	Conversion Of Preferred Dividends Payable To Common Stock Value ConversionOfPreferredDividendsPayableToCommonStockValue	4272421	usd
CY2022	ACON	Conversion Of Accrued Interest On Promissory Notes Value ConversionOfAccruedInterestOnPromissoryNotesValue	1855158	usd
CY2022	ACON	Issuance Of Common Stock And Warrants Related To Ipo Net Issuance Costs Value IssuanceOfCommonStockAndWarrantsRelatedToIpoNetIssuanceCostsValue	8552340	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	102000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	1280	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-530463	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-7068593	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2225958	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	2225958	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	456000	usd
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2023	us-gaap	Preferred Stock Redemption Discount PreferredStockRedemptionDiscount	1000	usd
CY2023	us-gaap	Preferred Stock Redemption Premium PreferredStockRedemptionPremium	1000	usd
CY2023	ACON	Commitment Shares Note Financing CommitmentSharesNoteFinancing	175619	usd
CY2023	ACON	Issuance Of Warrants Note Financing IssuanceOfWarrantsNoteFinancing	67500	usd
CY2023	ACON	Commitment Common Shares Equity Line Of Credit CommitmentCommonSharesEquityLineOfCredit	0	usd
CY2023	ACON	Common Share Issuance Costs Equity Line Of Credit CommonShareIssuanceCostsEquityLineOfCredit	-204647	usd
CY2023	ACON	Issuance Of Common Shares Equity Line Of Credit IssuanceOfCommonSharesEquityLineOfCredit	1462949	usd
CY2023	ACON	Cashless Exercise Of Prefunded Warrants CashlessExerciseOfPrefundedWarrants	0	usd
CY2023	ACON	Conversion Of Vested Restricted Stock Units To Common Shares ConversionOfVestedRestrictedStockUnitsToCommonShares	0	usd
CY2023	ACON	Common Share Stock Split Round Up CommonShareStockSplitRoundUp	0	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4911374	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-727995	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-7068593	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	162670	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	143622	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	456001	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1186658	usd
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	497656	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	0	usd
CY2023	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	-646319	usd
CY2022	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	usd
CY2023	ACON	Noncash Interest Related To Bridge Funding NoncashInterestRelatedToBridgeFunding	98685	usd
CY2022	ACON	Noncash Interest Related To Bridge Funding NoncashInterestRelatedToBridgeFunding	0	usd
CY2023	ACON	Warrants Issued As Noncash Finance Charge WarrantsIssuedAsNoncashFinanceCharge	72862	usd
CY2022	ACON	Warrants Issued As Noncash Finance Charge WarrantsIssuedAsNoncashFinanceCharge	0	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	102000	usd
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-0	usd
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-3789	usd
CY2023	ACON	Interest Conversion Discount Settled In Equity InterestConversionDiscountSettledInEquity	0	usd
CY2022	ACON	Interest Conversion Discount Settled In Equity InterestConversionDiscountSettledInEquity	1299507	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1491	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12290	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	38539	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	87522	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	220633	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-603102	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	448459	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-113893	usd
CY2023	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-6190	usd
CY2022	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	200712	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3646947	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4949112	usd
CY2023	us-gaap	Proceeds From Sale Of Furniture And Fixtures ProceedsFromSaleOfFurnitureAndFixtures	0	usd
CY2022	us-gaap	Proceeds From Sale Of Furniture And Fixtures ProceedsFromSaleOfFurnitureAndFixtures	1000	usd
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	119522	usd
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	208870	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-119522	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-207870	usd
CY2023	ACON	Bridge Funding Issuance Costs BridgeFundingIssuanceCosts	323301	usd
CY2022	ACON	Bridge Funding Issuance Costs BridgeFundingIssuanceCosts	-0	usd
CY2023	ACON	Equity Line Of Credit Issuance Costs EquityLineOfCreditIssuanceCosts	74916	usd
CY2022	ACON	Equity Line Of Credit Issuance Costs EquityLineOfCreditIssuanceCosts	-0	usd
CY2023	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	1462949	usd
CY2022	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	0	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	2250000	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1000	usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	usd
CY2023	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	1000	usd
CY2022	us-gaap	Payments For Repurchase Of Preferred Stock And Preference Stock PaymentsForRepurchaseOfPreferredStockAndPreferenceStock	-0	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	-0	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	365060	usd
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	-0	usd
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	2000000	usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	8552318	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3314732	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	6187258	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-451737	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1030276	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1482806	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	452530	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1031069	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1482806	usd
CY2023	ACON	Accrued Debt Issuance Costs Related To Bridge Funding AccruedDebtIssuanceCostsRelatedToBridgeFunding	22150	usd
CY2022	ACON	Accrued Debt Issuance Costs Related To Bridge Funding AccruedDebtIssuanceCostsRelatedToBridgeFunding	0	usd
CY2023	ACON	Accrued Debt Issuance Costs Related To Equity Line Of Credit AccruedDebtIssuanceCostsRelatedToEquityLineOfCredit	129731	usd
CY2022	ACON	Accrued Debt Issuance Costs Related To Equity Line Of Credit AccruedDebtIssuanceCostsRelatedToEquityLineOfCredit	0	usd
CY2023	ACON	Issuance Of Warrants Related To Bridge Funding IssuanceOfWarrantsRelatedToBridgeFunding	67500	usd
CY2022	ACON	Issuance Of Warrants Related To Bridge Funding IssuanceOfWarrantsRelatedToBridgeFunding	0	usd
CY2023	ACON	Original Issuance Discount15 Related To Bridge Funding OriginalIssuanceDiscount15RelatedToBridgeFunding	344118	usd
CY2022	ACON	Original Issuance Discount15 Related To Bridge Funding OriginalIssuanceDiscount15RelatedToBridgeFunding	0	usd
CY2023	ACON	Liability To Issue Common Shares LiabilityToIssueCommonShares	33297	usd
CY2022	ACON	Liability To Issue Common Shares LiabilityToIssueCommonShares	0	usd
CY2023	ACON	Issuance Of Commitment Shares Related To Bridge Funding IssuanceOfCommitmentSharesRelatedToBridgeFunding	175619	usd
CY2022	ACON	Issuance Of Commitment Shares Related To Bridge Funding IssuanceOfCommitmentSharesRelatedToBridgeFunding	0	usd
CY2023	ACON	Fair Value Of Warrants And Derivative Related To First Tranche Bridge Funding FairValueOfWarrantsAndDerivativeRelatedToFirstTrancheBridgeFunding	742988	usd
CY2022	ACON	Fair Value Of Warrants And Derivative Related To First Tranche Bridge Funding FairValueOfWarrantsAndDerivativeRelatedToFirstTrancheBridgeFunding	0	usd
CY2023	ACON	Fair Value Of Warrants And Derivative Related To Second Tranche Bridge Funding FairValueOfWarrantsAndDerivativeRelatedToSecondTrancheBridgeFunding	153810	usd
CY2022	ACON	Fair Value Of Warrants And Derivative Related To Second Tranche Bridge Funding FairValueOfWarrantsAndDerivativeRelatedToSecondTrancheBridgeFunding	0	usd
CY2023	ACON	Fair Value Of Warrants And Derivative Related To Third Tranche Bridge Funding FairValueOfWarrantsAndDerivativeRelatedToThirdTrancheBridgeFunding	160012	usd
CY2022	ACON	Fair Value Of Warrants And Derivative Related To Third Tranche Bridge Funding FairValueOfWarrantsAndDerivativeRelatedToThirdTrancheBridgeFunding	0	usd
CY2023	ACON	Dividends Accrued On Preferred Shares DividendsAccruedOnPreferredShares	0	usd
CY2022	ACON	Dividends Accrued On Preferred Shares DividendsAccruedOnPreferredShares	415523	usd
CY2023	ACON	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	0	usd
CY2022	ACON	Conversion Of Preferred Stock To Common Stock ConversionOfPreferredStockToCommonStock	25754379	usd
CY2023	ACON	Conversion Of Preferred Stock Dividends To Common Stock ConversionOfPreferredStockDividendsToCommonStock	0	usd
CY2022	ACON	Conversion Of Preferred Stock Dividends To Common Stock ConversionOfPreferredStockDividendsToCommonStock	4272421	usd
CY2023	ACON	Conversion Of Accrued Interest On Promissory Notes To Common Stock And Warrants ConversionOfAccruedInterestOnPromissoryNotesToCommonStockAndWarrants	0	usd
CY2022	ACON	Conversion Of Accrued Interest On Promissory Notes To Common Stock And Warrants ConversionOfAccruedInterestOnPromissoryNotesToCommonStockAndWarrants	1856438	usd
CY2023	ACON	Issuance Of Underwriters Warrants Related To Ipo IssuanceOfUnderwritersWarrantsRelatedToIpo	0	usd
CY2022	ACON	Issuance Of Underwriters Warrants Related To Ipo IssuanceOfUnderwritersWarrantsRelatedToIpo	199246	usd
CY2023	ACON	Designation Of Prepaid Expenses To Ipo Issuance Costs DesignationOfPrepaidExpensesToIpoIssuanceCosts	0	usd
CY2022	ACON	Designation Of Prepaid Expenses To Ipo Issuance Costs DesignationOfPrepaidExpensesToIpoIssuanceCosts	165403	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	556808	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	556808	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	381598	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	381598	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.82
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.82
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-19.61
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-19.61
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84C_eus-gaap--UseOfEstimates_zPDtw9OhJ8O6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_867_zH9AyPbGFeBg">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The financial statements include some amounts that are based on management's best estimates and judgments. The most significant estimates relate to depreciation, amortization, valuation of capital stock, and valuation of warrants and options to purchase shares of the Company's preferred and common stock. These estimates may be adjusted as more current information becomes available, and any adjustment could be significant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86D_zF4GNeg7lNn3"><b>Valuation of Derivative Instruments</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 815-40, <i>Derivatives and Hedging: Contracts on an Entity’s Own Equity</i>, addresses whether an equity-linked contract qualifies as equity in the entity’s financial statements. Agreements where an entity has insufficient authorized and unissued shares to settle the contract generally are accounted for as a liability and marked to fair value through earnings each reporting period. The Company evaluates its financial instruments to determine if such instruments are liabilities or contain features that qualify as embedded derivatives. For financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then revalued at each reporting date, with changes in the fair value reported as charges or credits to income.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023	us-gaap	Derivatives Reporting Of Derivative Activity DerivativesReportingOfDerivativeActivity	<p id="xdx_842_eus-gaap--DerivativesReportingOfDerivativeActivity_z1hA5hKAHpaf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><span id="xdx_865_zWtSvp6ZJ4bk">Derivative Financial Instruments</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has derivative financial instruments that are not hedges and do not qualify for hedge accounting. Changes in the fair value of these instruments are recorded in other income (expenses), on a net basis in the Consolidated Statements of Operations and Comprehensive Loss.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	761800	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1229000	usd
CY2023Q4	us-gaap	Restricted Cash RestrictedCash	10000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2023Q4	us-gaap	Cash Cash	1000000	usd
CY2022Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	1500000	usd
CY2023Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	204647	usd
CY2023Q4	us-gaap	Fair Value Net Asset Liability FairValueNetAssetLiability	410491	usd
CY2022Q4	us-gaap	Fair Value Hedge Liabilities At Fair Value FairValueHedgeLiabilitiesAtFairValue	0	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1056810	usd
CY2023	us-gaap	Fair Value Option Changes In Fair Value Gain Loss1 FairValueOptionChangesInFairValueGainLoss1	-646319	usd
CY2023Q4	us-gaap	Fair Value Hedge Liabilities At Fair Value FairValueHedgeLiabilitiesAtFairValue	410491	usd
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	13270	usd
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	18569	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	0	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13270	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18569	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	245030	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	199701	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	760535	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	462202	usd
CY2023Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	857722	usd
CY2022Q4	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	226469	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-562	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	521	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	0	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	36070	usd
CY2023	us-gaap	Operating Leases Income Statement Sublease Revenue OperatingLeasesIncomeStatementSubleaseRevenue	0	usd
CY2022	us-gaap	Operating Leases Income Statement Sublease Revenue OperatingLeasesIncomeStatementSubleaseRevenue	26340	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	55182	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	73372	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	53400	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	70026	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1782	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3346	usd
CY2023	us-gaap	Depreciation Depreciation	1564	usd
CY2022	us-gaap	Depreciation Depreciation	4500	usd
CY2022	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment	1000	usd
CY2023Q4	ACON	Future Depreciation Of Property And Equipment In Next Tweleve Months FutureDepreciationOfPropertyAndEquipmentInNextTweleveMonths	1186	usd
CY2023Q4	ACON	Future Depreciation Of Property And Equipment In Year Two FutureDepreciationOfPropertyAndEquipmentInYearTwo	596	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1782	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2272268	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	2152745	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1103645	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	942538	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1168623	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	1210207	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	161107	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	139121	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	169002	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	168951	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	168951	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	168951	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive	492768	usd
CY2023Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1168623	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	0	usd
CY2023Q4	us-gaap	Payments For Legal Settlements PaymentsForLegalSettlements	296313	usd
CY2023Q4	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	320561	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	2594118	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	0	usd
CY2023Q4	ACON	Unamortized Discounts And Deferred Financing Costs Warrants UnamortizedDiscountsAndDeferredFinancingCostsWarrants	-557582	usd
CY2022Q4	ACON	Unamortized Discounts And Deferred Financing Costs Warrants UnamortizedDiscountsAndDeferredFinancingCostsWarrants	0	usd
CY2023Q4	ACON	Unamortized Discounts And Deferred Financing Costs Derivative UnamortizedDiscountsAndDeferredFinancingCostsDerivative	-235628	usd
CY2022Q4	ACON	Unamortized Discounts And Deferred Financing Costs Derivative UnamortizedDiscountsAndDeferredFinancingCostsDerivative	0	usd
CY2023Q4	ACON	Unamortized Discounts And Deferred Financing Costs Issuance Cost UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost	-675184	usd
CY2022Q4	ACON	Unamortized Discounts And Deferred Financing Costs Issuance Cost UnamortizedDiscountsAndDeferredFinancingCostsIssuanceCost	0	usd
CY2023Q4	ACON	Unamortized Discounts And Deferred Financing Costs Total UnamortizedDiscountsAndDeferredFinancingCostsTotal	-1468394	usd
CY2022Q4	ACON	Unamortized Discounts And Deferred Financing Costs Total UnamortizedDiscountsAndDeferredFinancingCostsTotal	0	usd
CY2023Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	1125724	usd
CY2022Q4	us-gaap	Other Notes Payable Current OtherNotesPayableCurrent	0	usd
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	128057	shares
CY2023	us-gaap	Profit Loss ProfitLoss	-4911374	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-7484116	usd
CY2023	ACON	Weighted Average Number Of Shares Outstanding Basic1 WeightedAverageNumberOfSharesOutstandingBasic1	556808	shares
CY2022	ACON	Weighted Average Number Of Shares Outstanding Basic1 WeightedAverageNumberOfSharesOutstandingBasic1	381598	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	475488	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	355101	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	140980	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	29.47
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M12D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	33334	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	36.80
CY2022	ACON	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Options Granted SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOptionsGranted	P9Y7M6D
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	3138	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	20.32
CY2022	ACON	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Options Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOptionsForfeited	P5Y7M6D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	171176	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.07
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	0	shares
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	1720	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	23.64
CY2023	ACON	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term Options Forfeited SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermOptionsForfeited	P6Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	169456	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	31.15
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y6M
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	147977	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	30.57
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y4M24D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	226918	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	456001	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1186658	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.070	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.006	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.003	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Other EffectiveIncomeTaxRateReconciliationTaxCreditsOther	-0.003	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.268	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0	pure
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9235000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	479000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	9714000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9714000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	9714000	usd
CY2023	us-gaap	Valuation Allowances And Reserves Adjustments ValuationAllowancesAndReservesAdjustments	1315000	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001683168-24-001821-index-headers.html	Edgar Link	pending
0001683168-24-001821-index.html	Edgar Link	pending
0001683168-24-001821.txt	Edgar Link	pending
0001683168-24-001821-xbrl.zip	Edgar Link	pending
acon-20231231.xsd	Edgar Link	pending
acon_ex2301.htm	Edgar Link	pending
acon_ex2302.htm	Edgar Link	pending
acon_ex3101.htm	Edgar Link	pending
acon_ex3102.htm	Edgar Link	pending
acon_ex3201.htm	Edgar Link	pending
acon_ex3202.htm	Edgar Link	pending
acon_ex9701.htm	Edgar Link	pending
acon_i10k-123123.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
acon-20231231_cal.xml	Edgar Link	unprocessable
acon-20231231_def.xml	Edgar Link	unprocessable
acon-20231231_lab.xml	Edgar Link	unprocessable
acon-20231231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
acon_i10k-123123_htm.xml	Edgar Link	completed
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ACON
Aclarion, Inc. Stock $acon

2024 Q1 Form 10-K Financial Statement

#000168316824001821 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACON Aclarion, Inc. Stock $acon

2024 Q1 Form 10-K Financial Statement

#000168316824001821 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ACON
Aclarion, Inc. Stock $acon